An ‘Ozempic baby boom’? The GLP-1 pregnancy plot twist
Nov 9, 2026 · 12m
More Science podcasts · More News podcasts
Summary
Host Emily Kwong discusses the intersection of GLP-1 drugs and pregnancy with OBGYN Amy Valente, who contributed to new ACOG guidelines. They explore the "Ozempic baby" trend, noting that some GLP-1s may reduce the efficacy of oral contraceptives. The episode also covers how these medications benefit patients with PMOS and diabetes by improving fertility and pre-pregnancy health, while emphasizing the need to stop taking them before conception to ensure fetal safety.
Topics discussed
Intro: Con Ed sponsor and episode premise
The 'Ozempic Baby' phenomenon and patient confusion
Patient questions on stopping or restarting GLP-1s
AOG releases new guidance on GLP-1s and pregnancy
Sponsor announcements: Citi, Viking, and The Visitors
How GLP-1s affect oral contraceptive efficacy
Recommendations for alternative birth control methods
Benefits of GLP-1s for patients with PMOS (PCOS)
GLP-1s and diabetes management before pregnancy
Challenges of maintaining health off medication
AOG guidance: When to stop GLP-1s before pregnancy
Weight rebound and safety concerns during pregnancy
Nutritional risks of GLP-1s for fetal development
Why pregnancy research lags behind drug development
Closing remarks and show notes link
Credits and production team
Sponsor announcements: Google Workspace and Mint Mobile
More from Short Wave
Listen ad-free on Castria